Growth inhibitory effect of β-hydroxyisovalerylshikonin on prostate cancer cells and related mechanism

Journal of Shanghai Jiaotong University (Medical Science)

Volumn 30, Issue 5, 2010, Pages 527-530

  Liu, Xin ^a   Niu, Xin ^a   Zhou, Wen ^a   Yi, Jing ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

hydroxyisovalerylshikonin; Hypoxia inducible factor 1; Prostate cancer; Vascular endothelial growth factor

Indexed keywords

(3 HYDROXYISOVALERYL)SHIKONIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SHIKONIN DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

EID: 77954966630     PISSN: 16748115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Mulhall JP. Exploring the potential role of neuromodulatory drugs in radical prostatectomy patients[J]. J Androl, 2009,30(4):377-383.
2. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia[J]. Eur J Cancer, 2005,41(1):834-845.
3. Aragon-Ching JB, Dahut WL. Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression[J]? Cancer Ther, 2007,5A:151-160.
4. Mao X, Yu CR, Li WH, et al. Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells[J]. Cell Res, 2008,18(8):879-888.
5. Takai N, Ueda T, Nishida M, et al. Beta-hydroxyisovalerylshikonin has a profound anti-growth activity in human endometrial and ovarian cancer cells[J]. Gynecol Oncol, 2008,109(1):107-114.
6. Nakaya K, Miyasaka T. A shikonin derivative, beta- hydroxyisovalerylshikonin, is an ATP-non-competitive inhibitor of protein tyrosine kinases[J]. Anticancer Drugs, 2003,14(9):683-693.
7. Kajimoto S, Horie M, Manabe H, et al. A tyrosine kinase inhibitor, beta-hydroxyisovalerylshikonin, induced apoptosis in human lung cancer DMS114 cells through reduction of dUTP nucleotidohydrolase activity[J]. Biochim Biophys Acta, 2008,1782(1):41-50.
8. Komi Y, Suzuki Y, Shimamura M, et al. Mechanism of inhibition of tumor angiogenesis by beta-hydroxyisovalerylshikonin[J]. Cancer Sci, 2009,100(2):269-277.
9. Thomas R, Kim MH. HIF-1 alpha: a key survival factor for serum-deprived prostate cancer cells[J]. Prostate, 2008,68(13):1405-1415.